Jason E. Faris

7.8k total citations · 2 hit papers
47 papers, 1.8k citations indexed

About

Jason E. Faris is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jason E. Faris has authored 47 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Jason E. Faris's work include Pancreatic and Hepatic Oncology Research (19 papers), Colorectal Cancer Treatments and Studies (13 papers) and Cancer Genomics and Diagnostics (12 papers). Jason E. Faris is often cited by papers focused on Pancreatic and Hepatic Oncology Research (19 papers), Colorectal Cancer Treatments and Studies (13 papers) and Cancer Genomics and Diagnostics (12 papers). Jason E. Faris collaborates with scholars based in United States, Spain and Netherlands. Jason E. Faris's co-authors include Theodore S. Hong, Andrew X. Zhu, David P. Ryan, Bassel F. El‐Rayes, Peter J. Allen, Peter J. Hosein, Casper H.J. van Eijck, Julien Taı̈eb, Thierry Conroy and Lawrence S. Blaszkowsky and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jason E. Faris

47 papers receiving 1.8k citations

Hit Papers

FOLFIRINOX for locally advanced pancreatic cancer: a syst... 2016 2026 2019 2022 2016 2018 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
    2016 653 citations Mustafa Suker, Berend R. Beumer et al. The Lancet Oncology profile →
  2. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
    2018 362 citations Janet E. Murphy, Jennifer Y. Wo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jason E. Faris United States 17 1.5k 638 487 423 413 47 1.8k
Takeru Wakatsuki Japan 21 1.1k 0.8× 714 1.1× 319 0.7× 531 1.3× 162 0.4× 159 1.8k
Feng Du China 22 1.3k 0.9× 883 1.4× 503 1.0× 470 1.1× 162 0.4× 75 2.2k
Eun Yoon Cho South Korea 19 549 0.4× 384 0.6× 357 0.7× 254 0.6× 500 1.2× 50 1.6k
B. Massidda Italy 23 1.6k 1.1× 848 1.3× 662 1.4× 292 0.7× 156 0.4× 84 2.3k
Mashaal Dhir United States 21 690 0.5× 346 0.5× 302 0.6× 627 1.5× 272 0.7× 54 1.5k
Salvatore Artale Italy 18 1.9k 1.3× 648 1.0× 252 0.5× 780 1.8× 337 0.8× 41 2.3k
Zhenlin Yan China 20 697 0.5× 678 1.1× 346 0.7× 954 2.3× 428 1.0× 36 1.9k
Ming‐Chu Chang Taiwan 26 847 0.6× 284 0.4× 320 0.7× 854 2.0× 367 0.9× 69 1.9k
Feng-Hua Wang China 27 1.4k 0.9× 613 1.0× 825 1.7× 696 1.6× 213 0.5× 56 2.5k
Bhavana Konda United States 19 923 0.6× 387 0.6× 320 0.7× 328 0.8× 409 1.0× 73 1.7k

Countries citing papers authored by Jason E. Faris

Since Specialization
Citations

This map shows the geographic impact of Jason E. Faris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason E. Faris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason E. Faris more than expected).

Fields of papers citing papers by Jason E. Faris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason E. Faris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason E. Faris. The network helps show where Jason E. Faris may publish in the future.

Co-authorship network of co-authors of Jason E. Faris

This figure shows the co-authorship network connecting the top 25 collaborators of Jason E. Faris. A scholar is included among the top collaborators of Jason E. Faris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason E. Faris. Jason E. Faris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schöffski, Patrick, Nicole Concin, Cristina Suárez, et al.. (2021). A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Oncology Research and Treatment. 44(10). 547–556. 19 indexed citations
2.
Martinez, Elizabeth, et al.. (2020). 392 Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies. Regular and Young Investigator Award Abstracts. A238–A239. 11 indexed citations
3.
Almhanna, Khaldoun, David Wright, T. Macarulla Mercadé, et al.. (2017). A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Investigational New Drugs. 35(5). 634–641. 31 indexed citations
4.
5.
Murphy, Janet E., Jennifer Y. Wo, Cristina R. Ferrone, et al.. (2017). TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology. 35(4_suppl). 386–386. 17 indexed citations
6.
Faris, Jason E. & Ann S. LaCasce. (2017). Primary Mediastinal Large B-Cell Lymphoma. PubMed. 7(2). 343–353. 9 indexed citations
7.
Murphy, Janet E., Jennifer Y. Wo, David P. Ryan, et al.. (2017). FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology. 35(4_suppl). 368–368. 1 indexed citations
8.
Tabernero, Josep, Robin M.J.M. van Geel, Tormod Kyrre Guren, et al.. (2016). O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results. Annals of Oncology. 27. ii127–ii127. 5 indexed citations
9.
Suker, Mustafa, Eran Sadot, Lysiane Marthey, et al.. (2016). A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. HPB. 18. e342–e343. 5 indexed citations
10.
Almhanna, Khaldoun, Thea Kalebic, Cristina Cruz, et al.. (2016). Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clinical Cancer Research. 22(20). 5049–5057. 35 indexed citations
11.
Suker, Mustafa, Berend R. Beumer, Eran Sadot, et al.. (2016). FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. The Lancet Oncology. 17(6). 801–810. 653 indexed citations breakdown →
12.
13.
Almhanna, Khaldoun, Wells A. Messersmith, Jordi Rodón, et al.. (2014). MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.. Journal of Clinical Oncology. 32(15_suppl). 3546–3546. 7 indexed citations
14.
Russo, Andrea, Darrell R. Borger, Jackie Szymonifka, et al.. (2014). Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 120(10). 1482–1490. 62 indexed citations
15.
Faris, Jason E. & David P. Ryan. (2013). Controversy and Consensus on the Management of Patients With Pseudomyxoma Peritonei. Current Treatment Options in Oncology. 14(3). 365–373. 10 indexed citations
16.
Faris, Jason E., Jamie Arnott, Hui Zheng, et al.. (2011). A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Investigational New Drugs. 30(4). 1614–1620. 6 indexed citations
17.
Faris, Jason E. & Matthew R. Smith. (2010). Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Current Opinion in Endocrinology Diabetes and Obesity. 17(3). 240–246. 62 indexed citations
18.
Faris, Jason E. & M. Dror Michaelson. (2009). Sunitinib versus interferon-α in metastatic RCC. Nature Reviews Clinical Oncology. 7(1). 7–8. 9 indexed citations
19.
Faris, Jason E.. (2008). Lowering nursing injuries using post offer pre-employment testing. Work. 31(1). 39–45. 2 indexed citations
20.
Faris, Jason E., Allan F. Moore, & Gilbert H. Daniels. (2007). Sunitinib (Sutent)-Induced Thyrotoxicosis Due to Destructive Thyroiditis: A Case Report. Thyroid. 17(11). 1147–1149. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takeru Wakatsuki Breakdown of academic impact, for papers by Feng Du Breakdown of academic impact, for papers by Eun Yoon Cho Breakdown of academic impact, for papers by B. Massidda Breakdown of academic impact, for papers by Mashaal Dhir Breakdown of academic impact, for papers by Salvatore Artale Breakdown of academic impact, for papers by Zhenlin Yan Breakdown of academic impact, for papers by Ming‐Chu Chang Breakdown of academic impact, for papers by Feng-Hua Wang Breakdown of academic impact, for papers by Bhavana Konda
Rankless by CCL
2026